诚达药业
(301201)
| 流通市值：32.25亿 | | | 总市值：45.97亿 |
| 流通股本：1.09亿 | | | 总股本：1.55亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 182,452,989.75 | 76,307,845 | 333,131,182.38 | 243,768,662.64 |
| 营业收入 | 182,452,989.75 | 76,307,845 | 333,131,182.38 | 243,768,662.64 |
| 二、营业总成本 | 177,033,453.48 | 80,611,623.48 | 393,073,140.12 | 235,403,173.38 |
| 营业成本 | 92,128,552.24 | 39,627,889.42 | 190,482,603.64 | 137,620,876.91 |
| 税金及附加 | 2,459,270.57 | 424,558.48 | 4,281,592.87 | 2,274,425.31 |
| 销售费用 | 2,109,031.4 | 846,362.73 | 4,634,529.09 | 3,337,089.69 |
| 管理费用 | 60,644,094.14 | 30,808,110.88 | 104,004,017.1 | 65,621,516.21 |
| 研发费用 | 20,071,980.51 | 9,022,289.07 | 93,709,619.64 | 29,780,273.67 |
| 财务费用 | -379,475.38 | -117,587.1 | -4,039,222.22 | -3,231,008.41 |
| 其中:利息费用 | 1,209,519.16 | 605,056.97 | 295,338.26 | - |
| 其中:利息收入 | 881,048.83 | 485,623.61 | 2,026,669.84 | 1,668,431 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 2,964,478.63 | 477,755.54 | 1,603,689.96 | 4,972,835.53 |
| 加:投资收益 | 6,273,243.09 | 4,117,751.42 | 30,786,457.23 | 23,819,115.33 |
| 资产处置收益 | 37,332.75 | 34,493.74 | 204,739.69 | 204,739.69 |
| 资产减值损失(新) | -3,105,595.88 | -607,002.4 | -7,841,866 | -3,628,172.55 |
| 信用减值损失(新) | -1,078,905.09 | -1,850,222.64 | 4,755,949.59 | 5,975,640.27 |
| 其他收益 | 2,931,079.87 | 675,010.67 | 5,863,422.96 | 4,994,849.34 |
| 四、营业利润 | 13,441,169.64 | -1,455,992.15 | -24,569,564.31 | 44,704,496.87 |
| 加:营业外收入 | 1,169.32 | 625.47 | 60,865.27 | 11,713.64 |
| 减:营业外支出 | 507,061.76 | 80,313.42 | 2,674,358.85 | 2,279,295.31 |
| 五、利润总额 | 12,935,277.2 | -1,535,680.1 | -27,183,057.89 | 42,436,915.2 |
| 减:所得税费用 | -60,254.21 | -203,098.49 | 456,104.52 | 1,900,652.89 |
| 六、净利润 | 12,995,531.41 | -1,332,581.61 | -27,639,162.41 | 40,536,262.31 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 12,995,531.41 | -1,332,581.61 | -27,639,162.41 | 40,536,262.31 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 12,824,376.33 | -1,399,981.98 | -28,103,664.37 | 40,392,784.63 |
| 少数股东损益 | 171,155.08 | 67,400.37 | 464,501.96 | 143,477.68 |
| 扣除非经常损益后的净利润 | 2,899,028.34 | -5,854,136.86 | -57,671,784.99 | 14,431,722.4 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.08 | -0.01 | -0.18 | 0.27 |
| (二)稀释每股收益 | 0.08 | -0.01 | -0.18 | 0.27 |
| 八、其他综合收益 | - | - | -19,201,500 | - |
| 归属于母公司股东的其他综合收益 | - | - | -19,201,500 | - |
| 九、综合收益总额 | 12,995,531.41 | -1,332,581.61 | -46,840,662.41 | 40,536,262.31 |
| 归属于母公司股东的综合收益总额 | 12,824,376.33 | -1,399,981.98 | -47,305,164.37 | 40,392,784.63 |
| 归属于少数股东的综合收益总额 | 171,155.08 | 67,400.37 | 464,501.96 | 143,477.68 |
| 公告日期 | 2025-08-26 | 2025-04-25 | 2025-04-25 | 2024-10-29 |
| 审计意见(境内) | | | 标准无保留意见 | |